Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers

26 Aug 2025

Abstract excerpt

BACKGROUND: RSV/ΔNS2/Δ1313/I1314L (RSVt) (Sanofi) is a candidate live-attenuated intranasal respiratory syncytial virus (RSV) vaccine for infants and toddlers. METHODS: This phase I/II randomized clinical trial, conducted at sites in the United States (N=22), Chile (N=2), and Honduras (N=2), enrolled participants 6-18 months of age in four cohorts. In cohort 4, the primary cohort reported in this article,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to Sinusitis and nasal conditions
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40856556
DOI: 10.1056/evidoa2500026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Live-Attenuated Intranasal RSV Vaccine in Infants and ToddlersPMID 40856556Read ↗

Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenSemantic proximity Read ↗

A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of AgeSemantic proximity Read ↗

The long road to protect infants against severe RSV lower respiratory tract illnessSemantic proximity Read ↗

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenSemantic proximity Read ↗

A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 YearsSemantic proximity Read ↗

Impact of respiratory syncytial virus in the United States.Semantic proximity Read ↗

RSV--a substantial slice of the airway disease burden and the way to a vaccine.Semantic proximity Read ↗

Bivalent RSVpreF effectiveness against RSV-related lower respiratory tract disease hospitalization and ED visits across three RSV SeasonsSemantic proximity Read ↗

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in InfantsSemantic proximity Read ↗

Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus VaccinesSemantic proximity Read ↗

The burden of RSV-associated illness in children aged <5 years, South Africa, 2011 to 2016Semantic proximity Read ↗

New mucosal bivalent live-attenuated vaccine is protective against Human Metapneumovirus and Respiratory Syncytial VirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.